PreferredStockChannel
Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Sat, April 1, 4:05 PM
| This Slide: #526 of 609 |
Slide #526. Sabra Health Care REIT, Inc. — Preferred Stock Offering
Company:
Sabra Health Care REIT, Inc. (NASDAQ:SBRA)
Shares Offered:
5,000,000
Date of Pricing:
3/14/2013
Price Per Share:
$25
Preferred Stock Offering Details:
Sabra Health Care REIT, Inc. ("Sabra" or the "Company") (Nasdaq:SBRA) today announced the pricing of an underwritten public offering of 5,000,000 shares, or $125.0 million, of 7.125% Series A Cumulative Redeemable Preferred Stock (the "Series A Preferred Stock") at a price of $25.00 per share, pursuant to an effective registration statement. The Company granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its Series A Preferred Stock. The offering of 5,000,000 shares of Series A Preferred Stock is expected to close on March 21, 2013, subject to customary closing conditions.
Sabra Health Care REIT operates as a real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry. Co.'s main business consists of acquiring, financing and owning real estate property to be leased to third party tenants in the healthcare sector. Co.'s investment portfolio is comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements; investments in loans receivable; and preferred equity investments.
Preferred: SBRAP
Open the SBRA Page at Preferred Stock Channel »
|
|||||||||||||||||||||
|
|
Open the SBRA Page at Preferred Stock Channel (in a new window) »
 Free SBRA Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
Avg. Broker Rec.
  
|
Hold (2.50 out of 4) 10th percentile
(ranked lower than approx. 90% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|
|
